MedTech Startup Xyall Raises €7.6M To Expand Automated Tissue Dissection Solutions Globally

The funding round was led by Capricorn Partners through Capricorn Healthtech Fund II, with participation from existing investors including Sioux Technologies, BOM, Health Investment Partners and private backers.

Founded in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall automates and digitizes the tissue dissection process, helping pathologists achieve more accurate and reliable molecular diagnostic test results.

Read Also - Kyiv-Based Defence Tech Company The Fourth Law Raises Funding From US Firm Axon

According to Xyall, tissue dissection remains largely manual, labor-intensive, and prone to error and cross-contamination. In current clinical practice, pathologists mark Regions of Interest (ROIs) on H&E-stained slides, and lab technicians manually transfer these markings to dissection slides, scraping tissue for downstream analysis. This process is time-consuming, hard to scale, and further limited by a global shortage of laboratory technicians.

Xyall transforms this workflow by combining high-resolution slide imaging, precise image registration, workflow optimization, and high-precision robotics into a fully automated solution. Its Automated Tissue Dissection system accurately identifies and dissects ROIs, reduces technician workload, speeds up case processing, and eliminates cross-contamination risks.

The company’s first product, the Tissector High Throughput System, launched in 2021 for large molecular labs. It holds up to 1,800 slides, dissects more than 80 slides per hour with accuracy better than 0.1 mm, and can run unattended for three hours.

In 2023, Xyall introduced the Tissector Table Top (TT) for small to medium-sized labs. It holds 72 slides, dissects over 30 slides per hour with ≤0.1 mm accuracy, and runs uninterrupted for more than two hours.

With its latest funding, Xyall plans to expand the global rollout of the Tissector Table Top, which is already in use at over 15 molecular pathology labs across tier-1 commercial, academic, pharmaceutical, and research institutions in the United States.

Guido du Pree, CEO of Xyall, commented, “Over the past decade, PCR and next-generation sequencing technologies have advanced rapidly. However, the critical step of selecting tumour tissue for molecular analysis has remained largely manual, subjective and imprecise. With our fully automated tissue dissection solutions, Xyall provides the missing link between morphological and molecular diagnostics.”